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THE SURFACE ULTRASTRUCTURE
OF EXFOLIATED CERVICAL CELLS.
A. E. WILLIAMS, Teaching and Research
Centre, Western General Hospital, Edinburgh
and J. F. MURPHY, J. M. ALLEN and J. A.
JORDAN. Department of Obstetrics and
Gynaecology, University of Birmingham.
We have previously (Murphy et al.,
SEM/1ITRI. 1973, p. 605 and Br. J. Cancer,
1973, 28, 86) studied exfoliated cervical cells
by scanning electron microscopy (SEM).
Recently critical point drying has been
introduced and it has become possible to
stain cells before SEM study, thus making
identification easier.
Cell samples were prepared (1) by scraping
from the cervix, staining and processing for
SEM study and (2) by removing cells from
colposcopically directed areas on the cervix
with a membrane filter. A total of 138
patients were studied and characteristic
differences were noted between the surface
ultrastructure of benign and malignant cells.
Dyskariotic cells showed a mixture of surface
types between normal and frankly abnormal.
Differences were observed in the SEM
between cells that appeared identical by light
microscopy. In particular, a tendency to
surface abnormality existed on cells that
were normal by light microscopy when the
cells were adjacent to abnormal cells.
MEASUREMENT OF CARCINO-
EMBRYONIC ANTIGEN (CEA) IN
NORMAL SUBJECTS AND IN
VARIOUS NEOPLASTIC AND NON-
NEOPLASTIC DISORDERS. P. FRANCHI-
MONT, P. F. ZANGERLE, M. L. DEBRUCHE,
P. CONINX and J. PROYARD. Institut de
Medecine, University of Liege, Belgium.
A method of assay of CEA not requiring
prior extraction has been described. Various
essential criteria foravalidradioimmunoassay
have been fulfilled; the use of a preparation
of labelled CEA reasonably freed of contami-
nants and of molecules damaged by the
labelling reaction, acquisition of specific
antibodies, use of an efficient system of
separation of free labelled CEA from that
bound to antibody (the double antibody
technique) and application of the assay
method to biological fluids, in particular,
serum. The sensitivity ofthis method allows
the detection of 0 5-1 ng/ml of serum; the
precision and the reproducibility of the
results are very satisfactory.
CEA could be detected in the serum of
only 4.2% of 1017 normal subjects. The sera
of 205 patients suffering from a neoplasm
formally diagnosed were investigated: CEA
was found in the sera of 145, i.e. 70 7%.
Among these patients 24 were investigated
before any treatment: 21 had detectable
CEA concentrations (i.e. 87%). Of 54
patients with metastases 48 (i.e. 89%) had
detectable levels of CEA. The levels were
especially high when metastases were present:
61% ofthese patients had values greater than
10 ng/ml. The levels of CEA were also
measured in the sera of 43 patients during
treatment with cytostatic drugs. In the
non-neoplastic gastrointestinal disorders,
CEA was found in 29% of the sera and in
non-neoplastic lung disorders, 15.3% had
detectable CEA levels the values of which
were usually lower than 10 ng/ml. The assay
for CEA appears to be a useful method in the
diagnosis of cancerous diseases and the
follow-up of treatments in carcinoma.
CLINICAL EVALUATION OF CEA
IN URINE OF PATIENTS WITH
BLADDER CARCINOMA. C. B. KORSTEN,
J-P. PERSIJN and J. RENAUD. Netherlands
Cancer Institute, Amsterdam.
Urine from 73 patients was analysed for
CEA (carcinoembryonic antigen) using a
radioimmunoassay. The findings in 66






treatment State of disease infection infection
None No evidence of 0/11 5/5
bladder cancer
None Evidence of 8/8 4/4
bladder cancer
Yes No evidence of 2/21 3/3
recurrence of
the disease
Yes No evidence of 9/10 4/4
regression during
follow-up
In another group of 7 patients without
evidence of urinary infection CEA was
determined before and after therapy. In 5ABSTRACTS OF PROFFERED PAPERS 175
patients in whom treatment was successful
CEA excretion declined, contrary to the
remainder of this group, who showed both
progression of the disease and increase of
CEA.
It is concluded that CEA estimations are
highly valuable for diagnostic and follow-up
purposes in patients with bladder carcinoma
provided that urinary infections are absent.
RADIOIMMUNOASSAY OF HCG, of
AND f SUBUNITS IN CANCER. P.
FRANCHIMONT and A. REUTER. Institute of
Medicine, University of Liege, Belgium.
The specific measurement of ,B HCG and
native HCG is possible. We have prepared a
specific antiserum anti-HCG which does not
give any cross-reaction either with the other
glycoprotein hormones (follicle stimulating
hormone, FSH, luteinizing hormone, LH,
thyrostimulating hormone, TSH) or with cx
and ,8 subunits of HCG.
Another method for assaying native HCG
is to use a system constituted of labelled f
subunit with an anti-: subunit antiserum and
pure HCG as standard preparation. For the
specific measurement of P HCG subunit, we
use a homologous system in which the
glycoprotein hormones as well as of and P LH
subunits do not interfere. For the measure-
ment of the of subunit we have a less specific
system. However, correction is possible
knowing the normal interference in the sera
of normal healthy subjects and not pregnant
subjects.
Using these methods, we have detected
HCG, a and f subunits ofHCG in pathological
ranges in 81%, 100% and 75% in tropho-
blastic and embryonic tumours (21 cases)
respectively. In 78 patients with non-
trophoblastic tumours, native HCG ay and P
subunits HCG were respectively detected in
11%, 110% and 24% of the cases.
VAGINAL CYTOLOGIC EVALUATION
AS A PREDICTIVE TEST ON HOR-
MONE DEPENDENCY AND RESPON-
SIVENESS TO PROGESTOGENS OF
ENDOMETRIAL ADENOCARCINOMA.
P. IDE and J. BONTE. University of Louvain,
Belgium.
Progestogens seem to be very useful not
only as a complement to combined radio-
surgical therapy of localized endometrial
adenocarcinoma but also as an exclusive
treatment of recurrent or metastatic cancers.
Exclusive high dosage medroxyprogesterone
treatment brings about a significant remission
in almost 50% of the recurrent or metastatic
endometrial adenocarcinomata. Vaginal cy-
tological evaluation before andduringtherapy
has a striking prognostic value. In 57% of
the patients presenting an oestrogenic vaginal
smear (68% of total patient number) before
medroxyprogesterone treatment a significant
tumourremission is observed. Progestational
treatment changinganoestrogenic smeartoan
intermediate or to an atrophic one, or bring-
ing an intermediate smear to atrophy induces
a 92%, even a 100%, significant remission
rate. Return of the vaginal smear to an
oestrogenic aspect after withdrawing the
medroxyprogesterone therapy, or even during
this treatment, announces a new progression
of the adenocarcinoma.
CHARACTERIZATION OF IMMUNO-
COMPETENCE IN CANCER PAT-
IENTS. F. DE HALLEUX, C. DECKERS,
M. T. SIMON-MEULENBERGS and H. MAISIN.
Institut du Cancer, Louvain, Belgium.
Aiming towards a thorough evaluation of
the prognosis and the immunological ap-
proach of the therapy of cancer patients,
nonspecific as well as specific immune re-
actions have been investigated by in vivo and
in vitro tests.
The anamnestic response to PPD (purified
protein derivative) tuberculin was investi-
gated by Mantoux tests and leucocyte migra-
tion tests. The results show that for 19/38
patients with a positive Mantoux test the
average migration inhibition index was
12-43%. The 19 negative patients had an
average index of 1-23%. A primary response
was investigated by cutaneous sensitization
to DNCB (dinitrochlorobenzene). The
specific immune reactions were tested by
51Cr-release lymphocytotoxicity assay
against allogeneic tumour cells of the same
histological type. The lymphocytotoxicity
indices were above 30% for 6/10 melanoma
patients and 1/6 breast tumour patients.
No healthy individual nor patient with
unrelated tumour had an index above 28%.
Some correlation between these results and
the clinical status of the patients has been
observed, however, larger series will be needed
for demonstrative evidence.